[Photo -- From left to right: Epi Biotech CEO Jong-Hyuk Sung, GenScript ProBio Chairman Patrick Liu]

- GenScript ProBio Partners with Epi Biotech to Advance Hair Loss Antibody Therapy

- Commencing a Full-fledged Effort in Developing a Hair Loss Antibody Therapy through Collaboration with a Global multimodality CDMO Company

GenScript Probio announced on Nov 9th that it has signed an MOU with Epi Biotech to develop an antibody therapy for hair loss at the Epi Biotech's headquarters in Songdo.

Epi Biotech's strategy is to intensify the development of its own alopecia antibody new drug through collaboration with global biopharmaceutical companies. In particular, GenScript ProBio plans to develop humanized antibodies targeting CNTFR and bispecific antibodies based on the global human antibody library they possess. 

GenScript ProBio, a subsidiary of GenScript Biotech Corporation, offers end-to-end CDMO services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, vaccine and antibody protein drug, aiming to accelerate drug development for customers. GenScript ProBio has established companies in the United States, the Netherlands, South Korea, and China (Hong Kong, Shanghai, and Nanjing) and other regions to serve global customers, and has helped customers in the United States, Europe, Asia Pacific and other regions obtain more than 60 IND approvals since October 2017.

Epi Biotech is a company engaged in the research and development of various modalities of alopecia treatments. Epi Biotech possesses core technologies related to the self-developed alopecia/inflammation inhibitory cytokine antibodies (CytAb) and CXCL12-based bispecific antibody. EPI-005, one of its alopecia antibody therapeutic, was selected for the 2022 national novel drug development project by KDDF(Korea Drug Development Fund) and has successfully produced humanized antibodies, with recent patent registration completed. 

Patrick Liu, the Chairman of GenScript ProBio, said, “With the goal of innovation through collaboration, we will work together to shorten the development period of Epi Biotech's antibody therapeutics and ultimately strive to create a healthier future for patients suffering from hair loss.”

Jong-Hyuk Sung, CEO of Epi Biotech, expressed his expectations that “The likelihood of success in developing a new hair loss antibody drug will increase through our collaboration with GenScript ProBio, which has extensive experience in the development and commercialization of global antibody medicines.” He went on to say, “We will strive to develop hair loss treatments with a wider range of drug choices for patients, fewer side effects, and greater efficacy duration by collaborating with various biotech companies.